

Karen R Jacobson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9211100/publications.pdf>

Version: 2024-02-01

40
papers

966
citations

623188

14
h-index

454577

30
g-index

41
all docs

41
docs citations

41
times ranked

1417
citing authors

#	ARTICLE	IF	CITATIONS
1	Viral Dynamics of Omicron and Delta Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants With Implications for Timing of Release from Isolation: A Longitudinal Cohort Study. <i>Clinical Infectious Diseases</i> , 2023, 76, e227-e233.	2.9	38
2	Transmission Of Tuberculosis Among illicit drug use Linkages (TOTAL): A cross-sectional observational study protocol using respondent driven sampling. <i>PLoS ONE</i> , 2022, 17, e0262440.	1.1	1
3	The Impact of Alcohol Use Disorder on Tuberculosis: A Review of the Epidemiology and Potential Immunologic Mechanisms. <i>Frontiers in Immunology</i> , 2022, 13, 864817.	2.2	13
4	Testing and treatment for latent tuberculosis infection in people living with HIV and substance dependence: a prospective cohort study. <i>BMJ Open</i> , 2022, 12, e058751.	0.8	4
5	Spatial heterogeneity of extensively drug resistant-tuberculosis in Western Cape Province, South Africa. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
6	Symptom Screens Are Not Sufficient: The Fight Against Tuberculosis Needs Better Weapons. <i>Clinical Infectious Diseases</i> , 2021, 73, 121-123.	2.9	2
7	Decentralized Care for Rifampin-Resistant Tuberculosis, Western Cape, South Africa. <i>Emerging Infectious Diseases</i> , 2021, 27, 728-739.	2.0	7
8	Factors associated with phosphatidylethanol (PEth) sensitivity for detecting unhealthy alcohol use: An individual patient data meta-analysis. <i>Alcoholism: Clinical and Experimental Research</i> , 2021, 45, 1166-1187.	1.4	33
9	Alcohol and Tobacco Use in a Tuberculosis Treatment Cohort during South Africa's COVID-19 Sales Bans: A Case Series. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 5449.	1.2	10
10	Seroprevalence of SARS-CoV-2 IgG antibodies and risk factors in health care workers at an academic medical center in Boston, Massachusetts. <i>Scientific Reports</i> , 2021, 11, 9694.	1.6	23
11	Directly Observed Therapy to Measure Adherence to Tuberculosis Medication in Observational Research: Protocol for a Prospective Cohort Study. <i>JMIR Research Protocols</i> , 2021, 10, e24510.	0.5	0
12	Prevalence of elevated liver transaminases and their relationship with alcohol use in people living with HIV on anti-retroviral therapy in Uganda. <i>PLoS ONE</i> , 2021, 16, e0250368.	1.1	4
13	Tuberculosis Preventive Therapy for People With HIV Infection in High Tuberculosis Burden Settings: How Much Is Enough?. <i>Annals of Internal Medicine</i> , 2021, 174, 1462-1463.	2.0	1
14	Pandemic Response Requires Research Samples: A U.S. Safety-Net Hospital's Experience and Call for National Action. <i>Annals of Internal Medicine</i> , 2021, , .	2.0	2
15	376. Sensitivity and Specificity of the WHO Probable SARS-CoV-2 Case Definition Among Symptomatic Healthcare Personnel. <i>Open Forum Infectious Diseases</i> , 2021, 8, S290-S290.	0.4	0
16	Increasing Drug Resistance Among Persons With Tuberculosis in Massachusetts, 2009-2018. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa300.	0.4	0
17	Tuberculin skin test positivity among HIV-infected alcohol drinkers on antiretrovirals in south-western Uganda. <i>PLoS ONE</i> , 2020, 15, e0235261.	1.1	5
18	Title is missing!. , 2020, 15, e0235261.		0

#	ARTICLE	IF	CITATIONS
19	Title is missing!. , 2020, 15, e0235261.		0
20	Title is missing!. , 2020, 15, e0235261.		0
21	Title is missing!. , 2020, 15, e0235261.		0
22	Title is missing!. , 2020, 15, e0235261.		0
23	Title is missing!. , 2020, 15, e0235261.		0
24	Switching to bedaquiline for treatment of rifampicin-resistant tuberculosis in South Africa: A retrospective cohort analysis. PLoS ONE, 2019, 14, e0223308.	1.1	5
25	High mortality during tuberculosis retreatment at a Ghanaian tertiary center: a retrospective cohort study. Pan African Medical Journal, 2019, 33, 111.	0.3	6
26	Prevalence, Predictors, and Successful Treatment Outcomes of Xpert MTB/RIF-identified Rifampicin-resistant Tuberculosis in Post-conflict Eastern Democratic Republic of the Congo, 2012-2017: A Retrospective Province-Wide Cohort Study. Clinical Infectious Diseases, 2019, 69, 1278-1287.	2.9	16
27	Isoniazid Preventive Therapy for People With HIV Who Are Heavy Alcohol Drinkers in High TB-/HIV-Burden Countries: A Risk-Benefit Analysis. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 77, 405-412.	0.9	6
28	Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis. Lancet Respiratory Medicine, 2018, 6, 265-275.	5.2	80
29	Brief Report: Pulmonary Tuberculosis Is Associated With Persistent Systemic Inflammation and Decreased HIV-1 Reservoir Markers in Coinfected Ugandans. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 79, 407-411.	0.9	8
30	Impact of alcohol consumption on tuberculosis treatment outcomes: a prospective longitudinal cohort study protocol. BMC Infectious Diseases, 2018, 18, 488.	1.3	30
31	Using routinely collected laboratory data to identify high rifampicin-resistant tuberculosis burden communities in the Western Cape Province, South Africa: A retrospective spatiotemporal analysis. PLoS Medicine, 2018, 15, e1002638.	3.9	8
32	Implications of Failure to Routinely Diagnose Resistance to Second-Line Drugs in Patients With Rifampicin-Resistant Tuberculosis on Xpert MTB/RIF: A Multisite Observational Study. Clinical Infectious Diseases, 2017, 64, 1502-1508.	2.9	17
33	Fluoroquinolone Resistance Mutation Detection Is Equivalent to Culture-Based Drug Sensitivity Testing for Predicting Multidrug-Resistant Tuberculosis Treatment Outcome: A Retrospective Cohort Study. Clinical Infectious Diseases, 2017, 65, 1364-1370.	2.9	17
34	Gyrase Mutations Are Associated with Variable Levels of Fluoroquinolone Resistance in Mycobacterium tuberculosis. Journal of Clinical Microbiology, 2016, 54, 727-733.	1.8	65
35	Genetic Determinants of Drug Resistance in Mycobacterium tuberculosis and Their Diagnostic Value. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 621-630.	2.5	131
36	Scaling up multidrug-resistant tuberculosis care in China. The Lancet Global Health, 2015, 3, e183-e184.	2.9	2

#	ARTICLE	IF	CITATIONS
37	Implementation of GenoType MTBDRplus Reduces Time to Multidrug-Resistant Tuberculosis Therapy Initiation in South Africa. <i>Clinical Infectious Diseases</i> , 2013, 56, 503-508.	2.9	80
38	Alcohol, Hospital Discharge, and Socioeconomic Risk Factors for Default from Multidrug Resistant Tuberculosis Treatment in Rural South Africa: A Retrospective Cohort Study. <i>PLoS ONE</i> , 2013, 8, e83480.	1.1	45
39	Treatment Outcomes of Isoniazid-Resistant Tuberculosis Patients, Western Cape Province, South Africa. <i>Clinical Infectious Diseases</i> , 2011, 53, 369-372.	2.9	70
40	Treatment Outcomes among Patients with Extensively Drug-Resistant Tuberculosis: Systematic Review and Meta-Analysis. <i>Clinical Infectious Diseases</i> , 2010, 51, 6-14.	2.9	235